Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 26 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

31%

8 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

15 recruiting

Enrollment Performance

Analytics

N/A
9(45.0%)
Phase 4
5(25.0%)
Phase 2
3(15.0%)
Phase 3
3(15.0%)
20Total
N/A(9)
Phase 4(5)
Phase 2(3)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT07507825Phase 2Not Yet Recruiting

Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

Role: collaborator

NCT07413809Phase 3Recruiting

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Role: collaborator

NCT05722405Phase 4Recruiting

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Role: collaborator

NCT06520163Phase 3Recruiting

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Role: collaborator

NCT07088757Phase 4Recruiting

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

Role: collaborator

NCT05800353Not ApplicableCompleted

Nd:YAG Laser Vitreolysis for Symptomatic Vitreous Floaters

Role: lead

NCT06234514Phase 4Completed

Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab

Role: lead

NCT07078500Phase 2Recruiting

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT07022223Phase 2Recruiting

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Role: collaborator

NCT07003191Active Not Recruiting

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Role: collaborator

NCT06925334Phase 4Enrolling By Invitation

A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

Role: collaborator

NCT06452147Not ApplicableRecruiting

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

Role: collaborator

NCT05921682Recruiting

Early Body Temperature Targets and Relationship With Prognosis in Patients With Heat Stroke

Role: collaborator

NCT05923931Not ApplicableRecruiting

Non-inferiority Study of the Effect of Non-cooling Blanket on Body Temperature in Patients With Heat Stroke

Role: collaborator

NCT05921695Not ApplicableRecruiting

The Relationship Between Normal Saline Infusion and Acute Kidney Injury in Heat Stroke

Role: collaborator

NCT06537557Not ApplicableRecruiting

Application of an Early In-Hospital Temperature Management Protocol for Heat Stroke Patients

Role: collaborator

NCT06520176Phase 3Recruiting

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Role: collaborator

NCT06393855Not ApplicableRecruiting

Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain

Role: lead

NCT06463717Recruiting

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Role: collaborator

NCT04397211Not ApplicableActive Not Recruiting

Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease

Role: collaborator